{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+10", "query": { "condition": "Alzheimer Disease 10" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+10&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T09:05:35.536Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00141661", "title": "A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "PF-04494700 - Low Dose Arm", "type": "DRUG" }, { "name": "PF-04494700 - High Dose Arm", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 67, "start_date": "2005-10", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2009-08-20", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 12, "location_summary": "Sun City, Arizona • Fresno, California • San Diego, California + 9 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00141661" }, { "nct_id": "NCT01736579", "title": "Long-Term Study of IGIV, 10% in Alzheimer´s Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer´s Disease" ], "interventions": [ { "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "51 Years", "maximum_age": null, "sex": "ALL", "summary": "51 Years and older" }, "enrollment_count": 6, "start_date": "2012-11-29", "completion_date": "2013-06-04", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01736579" }, { "nct_id": "NCT00812565", "title": "Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "octagam 10%", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Octapharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 58, "start_date": "2009-02", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-05-05", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 1, "location_summary": "Hoboken, New Jersey", "locations": [ { "city": "Hoboken", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00812565" }, { "nct_id": "NCT00506415", "title": "Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Rivastigmine 5 cm^2", "type": "DRUG" }, { "name": "Rivastigmine 10 cm^2", "type": "DRUG" }, { "name": "Rivastigmine 15 cm^2", "type": "DRUG" }, { "name": "Placebo to 15 cm^2 patch", "type": "DRUG" }, { "name": "Placebo to 10 cm^2 patch", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 1584, "start_date": "2007-06", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2012-09-19", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00506415" }, { "nct_id": "NCT05637801", "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Alzheimer Disease 1", "Alzheimer Disease 2", "Alzheimer Disease 3", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Alzheimer Disease 9", "Alzheimer Disease 4", "Alzheimer Disease 7", "Alzheimer Disease 17", "Alzheimer's Dementia Late Onset", "Alzheimer Disease 5", "Alzheimer Disease 6", "Alzheimer Disease 8", "Alzheimer Disease 10", "Alzheimer Disease 11", "Alzheimer Disease 12", "Alzheimer Disease 13", "Alzheimer Disease 14", "Alzheimer Disease 15", "Alzheimer Disease 16", "Alzheimer Disease 18", "Alzheimer Disease 19", "Dementia", "Dementia Alzheimers", "Dementia, Mild", "Dementia of Alzheimer Type", "Dementia Moderate", "Dementia Senile", "Mild Cognitive Impairment", "Mild Dementia", "MCI", "Cognitive Impairment", "Cognitive Decline", "Cognitive Impairment, Mild" ], "interventions": [ { "name": "Spectris™ AD - Active", "type": "DEVICE" }, { "name": "Spectris™ AD - Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cognito Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 670, "start_date": "2022-12-13", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 68, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05637801" }, { "nct_id": "NCT00104273", "title": "Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dementia", "Alzheimer's Disease" ], "interventions": [ { "name": "Rasagiline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "45 Years to 90 Years" }, "enrollment_count": 376, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-07-15", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104273" }, { "nct_id": "NCT04100889", "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Disease", "Alzheimer Disease 1", "Alzheimer Disease 2", "Alzheimer Disease 3", "Alzheimer Disease 4", "Alzheimer Disease 5", "Alzheimer Disease 6", "Alzheimer Disease 7", "Alzheimer Disease 8", "Alzheimer Disease 9, Late-Onset", "Alzheimer Disease 10", "Alzheimer Disease 11", "Alzheimer Disease 12", "Alzheimer Disease 13", "Alzheimer Disease 14", "Alzheimer Disease 15", "Alzheimer Disease 16", "Alzheimer Disease 17", "Alzheimer Disease 18", "Alzheimer Disease 19", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Alzheimer Disease Focal" ], "interventions": [ { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "ProgenaBiome", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-02", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04100889" }, { "nct_id": "NCT01565330", "title": "A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "florbetapir F 18", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avid Radiopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 20, "start_date": "2008-03", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-06-18", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 3, "location_summary": "West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey", "locations": [ { "city": "West Palm Beach", "state": "Florida" }, { "city": "North East", "state": "Maryland" }, { "city": "Clementon", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01565330" }, { "nct_id": "NCT03432195", "title": "A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Donepezil TDS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 66, "start_date": "2018-01-31", "completion_date": "2018-06-28", "has_results": false, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03432195" }, { "nct_id": "NCT05043441", "title": "A Ten-Week Online Acceptance and Commitment Therapy Intervention for Family Caregivers of People With Dementia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depressive Symptoms" ], "interventions": [ { "name": "Acceptance and commitment therapy (ACT)", "type": "BEHAVIORAL" }, { "name": "Psychoeducation", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2022-03-21", "completion_date": "2024-06-18", "has_results": false, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-05-22T09:05:35.536Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05043441" } ] }